Neurocrine Biosciences (NBIX) Raw Materials (2018 - 2025)

Neurocrine Biosciences has reported Raw Materials for 8 years, with the latest figure at $31.9 million in Q1 2025.

• For the quarter ending Q1 2025, Raw Materials rose 76.24% year-over-year to $31.9 million; the trailing twelve-month figure through Mar 2025 stood at $31.9 million (up 76.24% YoY), and the FY2024 full-year result was $33.7 million, up 56.74% from the prior year.
• Raw Materials for Q1 2025 stood at $31.9 million, down from $33.7 million in the prior quarter.
• The five-year high for Raw Materials was $33.7 million in Q4 2024, with the low at $11.2 million in Q4 2021.
• Historically, Raw Materials has averaged $21.7 million across 5 years, with a median of $21.4 million in 2023.
• Annual changes were most pronounced in 2021 — Raw Materials sank 32.53% — and 2023, when it soared 79.17%.
• Neurocrine Biosciences' Raw Materials stood at $11.2 million in 2021, then increased by 7.14% to $12.0 million in 2022, then soared by 79.17% to $21.5 million in 2023, then surged by 56.74% to $33.7 million in 2024, then slipped by 5.34% to $31.9 million in 2025.
• The last three Raw Materials figures came in at $31.9 million (Q1 2025), $33.7 million (Q4 2024), and $23.7 million (Q3 2024), per Business Quant data.